Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
129 results about "Ocular inflammation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The term ocular inflammation refers to a group of conditions that can cause the eye to become red, swollen and inflamed. The most common of these conditions are uveitis and scleritis.
Cellular Constituents From Bacteroides, Compositions Thereof, and Therapeutic Methods Employing Bacteroides or Cellular Constituents Thereof
A cellular constituent is lysed from, produced by and / or isolated from one or more bacteria from the genus Bacteroides, and the cellular constituent, a derivative thereof, and / or one or more bacteria from the genus Bacteroides, or a modified form thereof, is employed in compositions and methods for modulating an inflammatory response. Such methods include methods of treating, delaying the onset of or reducing the symptoms of one or more inflammatory conditions / diseases, including corporal or gastrointestinal inflammation, for example, Irritable Bowel Syndrome, Crohn's Disease, or colitis, and / or associated diseases such diabetes, asthma, multiple sclerosis, cancer, rheumatoid arthritis, gingivitis, atopic diseases, for example, hay fever, food allergies, eczema, rhinitis, dermatitis, conjunctivitis, atopic syndrome and keratosis pelaris, ocular inflammatory disease, strokes, cardiovascular disease, depression, atherosclerosis and hypertension, and comprise administering a composition comprising one or more natural and / or modified bacteria of the genus Bacteroides, and / or a cellular constituent lysed from, produced by, or isolated from one or more natural and / or modified bacteria from the genus Bacteroides, or a derivative thereof.
Owner:MOORE RES ENTERPRISES
Inflammatory eye disorders
ActiveUS20130336557A1Improve reflectivityIncrease in sizeOrganic active ingredientsSenses disorderClinical studyOcular disease
Provided herein are methods of evaluating efficacy of a treatment in a subject having eye inflammation (e.g., a subject having dry eye syndrome) and selecting a subject for participation in a clinical study. Also provided are methods of treating a subject having eye inflammation (e.g., a subject having dry eye syndrome).
Owner:MASSACHUSETTS EYE & EAR INFARY
Bromfenac ophthalmic formulations and methods of use
InactiveUS20070287749A1Minimal and no irritationBiocideOrganic active ingredientsPhenylacetic acidBromfenac
Owner:SENJU PHARMA CO LTD +1
Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
InactiveUS20060014786A1Improve efficiencySustained levelBiocidePharmaceutical delivery mechanismOphthalmology4-Aminoquinoline
The present invention relates to novel ophthalmic pharmaceutical compositions comprising an inflammation-treating amount of a 4-aminoquinoline compound, derivative, isomers, or chemical salts, and methods for using these compositions for the treatment of ocular inflammatory conditions by topical administration directly to the eye.
Owner:RAUT RAJEEV
Reagents and methods to treat ocular diseases and infection
The invention provides compositions and methods of treating an ocular condition by administering to an eye of a patient having an ocular condition an effective amount of a catechin or polyphenol. The compositions and methods can be used to treat ocular conditions such as ocular infection, ocular inflammation, ocular cancer or benign eye tumors.
Owner:INSITE VISION
Viral Complement Control Proteins for Eye Disorders
InactiveUS20080075755A1Improve in vivo stabilityLow failure rateBiocideSenses disorderComplement control proteinOcular inflammation
The present invention provides compositions and methods for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
Owner:POTENTIA PHARMA INC
Method and apparatus for ocular surface imaging
The invention provides apparatuses and methods for detecting ocular surface defects. The methods and / or an apparatus of the invention can be used to detect ocular surface diseases, such as dry eye, uveitis, conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, meibomianitis, conjunctival hyperemia, eyelid hyperemia, ocular rosacea, ocular inflammation, or eye lid swelling.
Owner:ALCON INC
Compositions and methods for treatment of macular degeneration and related conditions
InactiveUS20090117171A1BiocideOrganic active ingredientsOcular neovascularizationOcular inflammation
The present invention provides methods and compositions for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization.
Owner:POTENTIA PHARMA INC
Use of Lacritin in Promoting Ocular Cell Survival
ActiveUS20070207522A1Promote ocular cell survivalPrevent and treat corneal infectionSenses disorderPeptide/protein ingredientsLacritinCell survival
The present invention relates to the use of lacritin, and fragments, derivatives, and homologs thereof, and nucleic acid sequences encoding that protein. The invention relates to the use of lacritin as a growth factor human corneal epithelial cells and other select epithelial cells. The invention also relates to the use of lacritin in promoting ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Cyclodextrin inclusion drug composition for ocular inflammation resistance
ActiveCN101757621AAchieve anti-inflammatory effectReduce elevationOrganic active ingredientsSenses disorderVitamin CGlucocorticoid
The invention relates to a cyclodextrin inclusion drug composition for ocular inflammation resistance, which consists of vitamin C or a derivative thereof as an active ingredient, glucocorticoid, cyclodextrin and one or more pharmaceutically acceptable pharmaceutical excipients capable of acting on eyes, wherein the glucocorticoid and / or the derivative of the vitamin C are included by the cyclodextrin.
Owner:TIANJIN JINYAO GRP
Lacritin-Syndecan Interactions
The present invention relates to methods and compositions useful for the regulation of lacritin, syndecan, and lacritin-syndecan interactions and the signaling pathway downstream of lacritin-syndecan interactions. The invention also relates to regulating lacritin-syndecan interaction to regulate ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Delivery of nrf2 as therapy for protection against reactive oxygen species
ActiveUS20170088593A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsOcular neovascularizationOcular inflammation
The present invention provides methods and compositions for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye
The present invention relates to compositions comprising a proanthocyanidin, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. The present invention also relates to compositions comprising a proanthocyanidin, glycyrrhetinic acid and telmesteine, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye.
Owner:SINCLAIR PHARMA
Copper chelators for treating ocular inflammation
InactiveUS7754765B2Inhibit ocular inflammatory responseInhibit the inflammatory responseBiocideLaser surgeryPenicillamineCopper Chelator
In various aspects, the invention provides methods for treating ocular inflammation using copper chelating compounds, such as compounds other than D-penicillamine. In some embodiments, such compounds may be polyamines, such as triethylenetetramine or tetraethylenepentamine. For example, the present invention provides methods for treating inflammation secondary to ocular laser therapy.
Owner:LI NING DR
RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions
RNA interference is provided for inhibition of tumor necrosis factor alpha (TNFalpha) by silencing TNFalpha cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFalpha converting enzyme (TACE / ADAM17) mRNA expression. Silencing such TNFalpha targets, in particular, is useful for treating patients having a TNFalpha-related condition or at risk of developing a TNFalpha-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
Owner:ARROWHEAD RES CORP
Viral complement control proteins for eye disorders
InactiveUS8043609B2Improve in vivo stabilityLow failure rateBiocideSenses disorderComplement control proteinOcular inflammation
The present invention provides compositions and methods for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
Owner:POTENTIA PHARMA INC
Treatment of ocular inflammatory diseases using laquinimod
InactiveUS20130324574A1Improve oral bioavailabilityBiocideSenses disorderDiseaseViral Conjunctivitis
Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway. This application also provides a method for treating a subject suffering from an autoimmune disease-associated ocular inflammation comprising periodic ocular administration to the subject a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt, and an ocular pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating an autoimmune disease-associated ocular inflammation.
Owner:TEVA PHARMA IND LTD
Pharmaceutical Composition of Ibuprofen and Tramadol for Ophthalmic Use
The present invention relates to a pharmaceutical composition of ibuprofen and tramadol for ophthalmic use. Said composition is effective and safe for the treatment of ocular inflammation and / or pain associated to different diseases or pathological states which affect the eye area In particular, the ophthalmic composition of the invention is indicated, for example, for the treatment of pain and / or inflammation after eye surgery.
Owner:FARMALIDER
Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist
The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (κ) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said short-chain peptides, and pharmaceutical compositions containing them and their use.
Owner:CADILA HEALTHCARE LTD
Novel compositions and therapeutic methods
ActiveUS20170281667A1Good anti-inflammatory activityReduced VEGF expressionAntibacterial agentsOrganic active ingredientsAutoimmune responsesAutoimmune thyroid disease
The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and / or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and / or any disorder associated with inflammation, immunomodulation and microbial infection.
Owner:AYUVIS RES INC
Composition for treating fundus macular oedema and application of composition to treating eye diseases
ActiveCN103565801AGood for healthImprove microcirculationSenses disorderHydroxy compound active ingredientsIntra ocular pressureDisease
The invention discloses a composition for treating fundus macular oedema and application of the composition in treatment of eye diseases and belongs to the technical field of medicines. The composition for treating the fundus macular oedema comprises the following components in percentage by weight: 0.4-71% of (a) polyphenolic compounds, 0.6-93% of (b) lipoic acid, dihydrolipoic acid, lipoic acid salt or lipoamide, 0-97% of (c) ubiquinone or panthenol and 0-87% of (d) docosahexaenoic acid or ethyl ester thereof and / or timnodonic acid or ethyl ester thereof. The composition can be used for improving patient visual acuity, stabilizing intraocular pressure and reducing various ocular inflammations such as the fundus macular oedema. By means of the composition for treating the fundus macular oedema and a treatment method, the fundus macular oedema can be prevented, stabilized, controlled or treated and the fundus health can be enhanced; in the meantime, the intraocular pressure can be stabilized, the vision can be maintained or improved, various eye diseases or macular oedema and inflammation which are caused by eye operations can be reduced; the diabetic complication is also treated, the blood microcirculation is promoted and the liver function is improved.
Owner:陈井然
Methods for Treating Ocular Inflammation by Neutralizing Cxcl10 Activity
InactiveUS20080019973A1Reduce inflammationReduce corneal inflammationCompound screeningApoptosis detectionCXCL10Ocular inflammation
The invention provides a method of reducing ocular inflammation in an individual susceptible to ocular inflammation. The method involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Also provided is a method for reducing spread of viral infection within ocular tissues of an individual susceptible to ocular viral infection, which involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Further provided is a method of extending corneal graft survival following corneal transplantation in an individual, which involves administering to said individual an effective amount of a neutralizing agent specific for CXCL10. Additionally, the invention provides a method for identifying a compound for reducing ocular inflammation in an animal.
Owner:LANE THOMAS E +1
Use of lacritin in promoting ocular cell survival
The present invention relates to the use of lacritin, and fragments, derivatives, and homologs thereof, and nucleic acid sequences encoding that protein. The invention relates to the use of lacritin as a growth factor human corneal epithelial cells and other select epithelial cells. The invention also relates to the use of lacritin in promoting ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Delivery of Nrf2 as therapy for protection against reactive oxygen species
ActiveUS11053291B2Polypeptide with localisation/targeting motifPeptide/protein ingredientsOcular neovascularizationOcular inflammation
The present invention provides methods and compositions for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Eye drop composition for treating ocular inflammatory disease and preparation method therefor
ActiveUS20160193234A1Eliminate side effectsEasy to useOrganic active ingredientsBiocideHyaluronic acidInflammation
The present invention relates to a composition for treating an ocular inflammatory disease, comprising hydrophilic sulfasalazine and hyaluronic acid, and a preparation method therefor. Furthermore, the present invention relates to a method for treating an ocular inflammatory disease, which comprises administering, to an individual, a therapeutically effective amount of hydrophilic sulfasalazine and hyaluronic acid.
Owner:THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOPERATION FOUND
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
Owner:ARROWHEAD RES CORP
Sap and peptidomimetics for treatment of eye disease
Self-assembling peptides or self-assembling peptidomimetics ("SAP") can treat or alleviate disease, disorder, injury or one or more symptoms of diseases or disorders of the eye, including ocular inflammation, dry eye, corneal erosion, retinal detachment, and other problems where the barrier formed by the SAP provides protection and aids healing. SAP topical or injectable compositions of SAP for local administration to the eye include SAP in an amount and concentration effective to provide an SAP structure on or within the eye or a compartment or structure thereof. The SAP can be assembled prior to or after the composition is administration. SAP can also be used as coatings for contact lens, intraocular lens, and wound healing devices, to enhance healing and decrease inflammation.
Owner:ARCH BIOSURGERY
Use of huperzine A in the preparation of medicines for treating glaucoma and/or ischemia-induced optic nerve damage
InactiveCN102258518AShrink the pupilLower eye pressureOrganic active ingredientsSenses disorderIntraocular pressureApoptosis
The invention relates to the field of medical technology, and relates to the effective monomer component of lycopodium alkaloids isolated from Chinese folk herbal medicine Huperzia Serrata - huperzine A ((-)-huperzineA) in the preparation of treatment of glaucoma and / or Or use in medicine for ischemia-induced optic nerve damage. The structural formula of the compound huperzine A involved in the present invention is as follows. Experiments have confirmed that huperzine A has significant miotic effect and intraocular pressure-lowering effect on glaucoma animal models, and has obvious protective effects on retinopathy and apoptosis inflammatory protein expression in animals induced by ischemia or high intraocular pressure. Developed as a new drug for the treatment of glaucoma and / or ischemia-induced optic nerve damage. Huperzine A (-)-Huperzine A.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions
The present invention provides a RNA interferencefor inhibition of tumor necrosis factor a (TNFa) by silencing TNFa cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFa converting enzyme (TACE / ADAM17) mRNA expression. Silencing such TNFa targets, in particular, is useful for treating patients having a TNFa-related condition or at risk of developing a TNFa-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
Owner:ARROWHEAD RES CORP
Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
A composition for treating or controlling an ocular disease or condition comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), which disease or condition has an etiology, or results, in inflammation. The composition can optionally include an anti-inflammatory agent, an anti-infective agent, or both. The composition can be formulated for topical application, injection, or implantation in an affected eye to treat or control the ocular inflammatory disease or condition.
Owner:BAUSCH & LOMB INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com